You are using an outdated browser. Please upgrade your browser to improve your experience.

Tclin
IFNAR2
Interferon alpha/beta receptor 2

Protein Summary
Description
Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation (PubMed:26424569). Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1 (PubMed:8181059, PubMed:7665574, PubMed:7759950). Isoform 3 is a potent inhibitor of type I IFN receptor activity (PubMed:7759950). The protein encoded by this gene is a type I membrane protein that forms one of the two chains of a receptor for interferons alpha and beta. Binding and activation of the receptor stimulates Janus protein kinases, which in turn phosphorylate several proteins, including STAT1 and STAT2. Multiple transcript variants encoding at least two different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Uniprot Accession IDs
Gene Name
Ensembl ID
  • ENST00000342101
  • ENSP00000343289
  • ENSG00000159110
  • ENST00000342136
  • ENSP00000343957
  • ENST00000382264
  • ENSP00000371699
  • ENST00000404220
  • ENSP00000384309

Symbol
  • IFNABR
  • IFNARB
  • IFN-R
  • IMD45
  • IFNABR
  • IFNARB
  • IFN-alpha-REC
Illumination Graph
Knowledge Table
Most Knowledge About
Knowledge Value (0 to 1 scale)
virus perturbation
0.83
hub protein
0.82
transcription factor binding site profile
0.8
PubMedID
0.78
kinase perturbation
0.71


IDG Development Level Summary
Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 167.9   (req: < 5)
Gene RIFs: 52   (req: <= 3)
Antibodies: 352   (req: <= 50)
Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 167.9   (req: >= 5)
Gene RIFs: 52   (req: > 3)
Antibodies: 352   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 12
Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligand: 0
Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drugs: 6
Protein Data Bank (9)
1 – 5 of 9
PDB Structure Id
Ligand
Method
Resolution (Å)
M.W. (kDa)
Pub Year
Title
PDB Structure Id
M.W.
Resolution
Pub Year
Pathways (37)
Cytokine Signaling in Immune system (R-HSA-1280215)

Click on a row in the table to change the structure displayed.

Items per page:
1 – 5 of 5
Data Source
Name
Explore in Pharos
Explore in Source
Reactome
Cytokine Signaling in Immune system
Reactome
Immune System
Reactome
Interferon Signaling
Reactome
Interferon alpha/beta signaling
Reactome
Regulation of IFNA signaling
Name
Explore in Pharos
Explore in Source
Cytokine Signaling in Immune system
Immune System
Interferon Signaling
Interferon alpha/beta signaling
Regulation of IFNA signaling
Protein-Protein Interactions (124)
1 – 10 of 124
GRAP2
Tbio
Novelty: 0.00186531
p_int: 0.9994602
p_ni: 0.0005398
Score: 0.307
Data Source: BioPlex,STRINGDB
IFNAR1
Tclin
Novelty: 0.00224149
Score: 0.998
Data Source: Reactome,STRINGDB
IFNA2
Tbio
Novelty: 0.00041727
Score: 0.993
Data Source: STRINGDB
STAT2
Tbio
Family: TF
Novelty: 0.00332089
Score: 0.99
Data Source: Reactome,STRINGDB
JAK1
Tclin
Family: Kinase
Novelty: 0.00136831
Score: 0.987
Data Source: Reactome,STRINGDB
IFNW1
Tbio
Novelty: 0.09580093
Score: 0.984
Data Source: STRINGDB
IRF9
Tbio
Family: TF
Novelty: 0.01154411
Score: 0.982
Data Source: STRINGDB
STAT1
Tchem
Family: TF
Novelty: 0.00041067
Score: 0.981
Data Source: Reactome,STRINGDB
TYK2
Tclin
Family: Kinase
Novelty: 0.00331363
Score: 0.981
Data Source: Reactome,STRINGDB
IFNB1
Tbio
Novelty: 0.00013983
Score: 0.975
Data Source: Reactome,STRINGDB
Publication Statistics
PubMed Score  167.90

PubMed score by year
PubTator Score  153.91

PubTator score by year
Amino Acid Sequence
Residue Counts
Sequence
MLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHSIVPTHYTLLY
1-70
TIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLFSCSHNFWLAIDMSFEPPEFE
70-140
IVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKKHKPEIKGNMSGNFTYIIDKLIPNTNYCVSV
140-210
YLEHSDEQAVIKSPLKCTLLPPGQESESAESAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVL
210-280
NFHNFLAWPFPNLPPLEAMDMVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQA
280-350
SATSTESQLIDPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR
350-420
ITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPTFPSPSSEGLW
420-490
SEDAPSDQSDTSESDVDLGDGYIMR
490-515
MLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHSIVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLFSCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKKHKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAESAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMDMVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLIDPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGRITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPTFPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR